Diana Merino Vega

A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making.

E. Sigal, D. Glass, M. Stewart, 2020, American health & drug benefits.

Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making

N. Russell, T. Leblanc, R. Walter, 2022, Oncology and Therapy.

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

Edward S. Kim, R. Schilsky, Caroline Schenkel, 2021, Clinical Cancer Research.

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

G. Rosner, A. Chaudhuri, G. Pennello, 2022, JCO precision oncology.

Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making

N. Russell, T. Leblanc, R. Walter, 2022, Oncology and Therapy.

Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.

A. Stenzinger, J. Budczies, Mingchao Xie, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Edward S. Kim, R. Schilsky, R. Osarogiagbon, 2021, Clinical Cancer Research.